Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Transplant Cell Ther. 2021 Nov 11;28(2):109.e1–109.e8. doi: 10.1016/j.jtct.2021.11.002

Figure 1: Trial two-unit UCB and trial Haplo-BM transplantation.

Figure 1:

1A: Non-relapse mortality after two-unit UCB (24%, 9% CI 18-31) and Haplo-BM (10%, 95% CI 5-15) transplants

1B: Relapse/progression after two-unit UCB (50%, 9% CI 43-58) and Haplo-BM (53%, 95% CI 45-61) transplants

1C: Progression-free survival after two-unit UCB (29%, 9% CI 22-35) and Haplo-BM (37%, 95% CI 29-45) transplants

1D: Overall survival after two-unit UCB (36%, 9% CI 29-44) and Haplo-BM (42%, 95% CI 33-51) transplants